Aspen acquires anticoagulant brands


South African generics manufacturer Aspen has bought two heparin-derived thrombosis drugs from GlaxoSmithKline (GSK). The £700 million deal includes Arixtra (fondaparinux) and Fraxiparine (nadroparin), as well as a manufacturing site in Notre-Dame de Bondeville, France.

Earlier this year, Aspen agreed a similarly large deal with MSD, the European subsidiary of Merck & Co, for a bundle of other drug brands and a manufacturing site in the Netherlands, which also produces heparin-based ingredients. ‘This deal presents excellent synergistic opportunities for Aspen’s ongoing global expansion strategy,’ said Aspen’s chief executive Stephen Saad in a statement. Together, the two deals will allow the firm to ‘pursue a more vertically integrated supply chain for heparin based products’.

GSK will retain distribution rights for the two drugs in China, Pakistan and India.

 


Related Content

Aspen in $1 billion deal with Merck

1 July 2013 Business

news image

South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker

Business roundup

27 January 2012 Business

news image

Industry news, February 2012

Most Commented

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint

Shadow of Chernobyl

26 April 2016 Critical Point

news image

Mark Peplow takes the long view on the cost of nuclear power